martedì, 16 aprile 2024
29 Giugno 2018

FDA Approves Binimetinib/Encorafenib for BRAF+ Melanoma

June 27, 2018 – The FDA has approved the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib for the treatment of patients with BRAF-mutant unresectable or metastatic melanoma, as detected by an FDA-approved test. The approval is based on the phase III COLUMBUS trial, in which at a median follow-up of 36.8 months, combining encorafenib at 450 mg daily and binimetinib at 45 mg twice daily (COMBO450) reduced the risk of death by … (leggi tutto)